Severe infections are an established risk of immunosuppressive therapy; however, the risk of opportunistic infections in patients with IBD who receive immunosuppressive therapy has so far only been studied retrospectively. The increased incidence of herpes flares and development or worsening of viral warts in patients with IBD who receive azathioprine has now been demonstrated for the first time in a prospective study.
